InvestorsHub Logo
Followers 59
Posts 11472
Boards Moderated 0
Alias Born 07/16/2006

Re: None

Monday, 05/22/2017 7:22:01 AM

Monday, May 22, 2017 7:22:01 AM

Post# of 20689
Momenta downgraded to Equal Weight from Overweight at Barclays

Barclays analyst Douglas Tsao downgraded Momenta Pharmaceuticals (MNTA) to Equal Weight citing the likelihood of generic manufacturers, most notably Mylan (MYL), winning approval for generic Copaxone in the coming months. The approvals could come before Momenta and its partner Sandoz win approval themselves for the 40mg dose, Tsao tells investors in a research note.

He lowered his price target for the shares to $17 from $20.

Read more at:
https://thefly.com/landingPageNews.php?id=2555570